Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shareholders are the losers again... Only so many hits left in the wagon.
Leo needs to find a solution for the OTCBB... If not, then he might as well sell out or fold...
It's a shame when manipulators control the show. Leo's biggest blunder was not moving off-the-pinks...
Puts to rest the Mako attack...Even though K/B stand to make more money, P demonstrated that CTIX is no scam...
Great results!!! P is a winner for the future, now the negotiations begin...
2 press releases on P results (so far) are clues for great results. Leo knew more than he was letting on.
Up 1.47 percent! Nice try DUD!!! Must be the only Mako relative left posting here.
The price is holding up well, my guess is positive results. Wednesday PR!!!
Leo has to know the results by now... It will be interesting to see when he issues the results? There's no stock halts on the pinks, so negative results could get ugly... Hope for the best and prepare for the worst...
Don't think we'll see 1.60 in a week? The range negative/positive some have discussed, "including the SA article" will 1.20 to 2 plus. Interesting how the PPS settled in that mid point last Friday.
Cellceutix mentioned for ovarian cancer market outlook analysis...
https://www.whatech.com/market-research/medical/162207-2016-pipeline-of-metastatic-ovarian-cancer-market-outlook-analysis
Companies involved in this research Cellceutix Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals, Inc., MolMed S.p.A., Natco Pharma Limited, Northwest Biotherapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd. and VG Life Sciences, Inc.
The report provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects.
Get this research at http://www.rnrmarketresearch.com/contacts/discount?rname=544938 .
Scope for this research:
The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
The report reviews pipeline therapeutics for Metastatic Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Metastatic Ovarian Cancer therapeutics and enlists all their major and minor projects
The report assesses Metastatic Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Question for the board? Would it be legal to disclose the data "to anyone" ahead of a PR? I'm assuming if shares are not bought by the known parties it's OK? Would be hard "for the SEC" to find out everyone who might know? You see this all the time with M & A activity... The volume is usually heavy ahead of any announcement... We might get a clue (stock direction) before the PR? Also, why the second PR when the announcement was always going to be May? A clue from the CEO to load-the-boat?
There's many reasons for the so-called low-price... Singling a chat-board for the main reason is comical. The PPS can be contributed to low exposure (OTCBB) and trading below 5 bucks. Leo's failure to up-list last year a big factor. A patent settlement awarded to the Aruda family "many millions" of shares. Stock dilution since there's no revenues... Pending lawsuits from a bogus article... Add that all up and it equals 1.63... Exactly why there's a market to determine a value. Leo delivers the goods and it goes much higher.
12 years? This year is the make-or-break year for CTIX. No more skating on thin ice in penny-land... The next financial deal depends on a partnership or up-listing... We will know by years end if Leo can achieve either or both?
Leo's possible clues in his last PR? Reading the second part again (bold) It's my opinion, by hinting at other projects ready to fire up, there has to be a large cash infusion on-the-way...
(Marketwired - May 11, 2016) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.
Separately in Cellceutix's dermatology pipeline, the Company last month reactivated a request for a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) to discuss initiating clinical research of Brilacidin, Cellceutix's lead defensin mimetic, for the treatment of the inflammatory skin condition hidradenitis suppurativa. Cellceutix previously filed the request, ultimately electing to hold off on clinical studies of Brilacidin for dermatological uses until several other clinical trials sponsored by the Company were completed or neared completion. Cellceutix anticipates the meeting to transpire in June 2016 and will be submitting a Briefing Book to the FDA on the planned trial one month prior to the meeting.
Sell the news happened last-week after Leo's PR. Poitive results should trigger a rally past 2. Leo would not have mentioned "partner" if there were no listeners.
Greatest wealth created is by the obscure names. CTIX is not a known name yet in the investment world. The Mako gang have held this back since last August. Can only keep a sleeping giant down so long....
I agree LR... Also, What purpose did Leo serve by issuing a PR to remind the public about P results? After all, the original forecast mentioned May results... An early X-mas gift to buy shares...
That's great, more cheap shares to buy... Hopefully, your prediction is wrong again...
Pfizer and 50 other large/medium size drug/biotech companies. Cheaper to let others build the pipeline for you...
5.2 billion divided by 120 mil shares= 43... off a bit...
Ctix's pipeline more robust than Anacor... A 5.2 billion valuation on CTIX would be close to 45... Amazing the potential here...
http://finance.yahoo.com/q?s=ANAC
Tombrady, Great points! The great science thesis for owning shares has not contributed much to the PPS. I blame this on Leo... His handling of "press releases" seems/ed to be driven by chat-boards more than facts release. He screwed up the up-listing process by dealing his hand to the shorts/doubters... Never should he have announced his intentions to up-list. That fueled speculation (bull/bear) that led to the undoing... Leo did not have all his-ducks-in-order when the big rally of 2014 hit. Meaning, company structure to up-list. The BOD's were never in place when Leo issued a PR to file an application. Leo is not my choice to lead this company to the next phase, but we're stuck with him due to the logistics. The inability to up-list help trigger the Mako attack (my opinion) and has probably shed 2 or 3 dollars off the PPS. Now, this company is dependent on a partnership for cash projects than "traditional borrowing" due to OTCBB manipulation. The P results will be a difference maker either way (bull/bear)... This is Custards Last Stand. Make or break time the next few weeks..
Haven't heard from Milkdud this afternoon. His forecast has gone array.
I disagree, they have tons of projects on-hold because funds are dry. If Leo's strategy is to sell the company (cash-out) then they're OK... However, some here are hinting at CTIX becoming more than a pipe-line for others. That will take big bucks, something they don't have without diluting shares on a criminal market.
A RS to up-list is better than dying in penny-land trying to raise capital. Some here are missing the strategy behind up-listing. Hopefully, it won't come to that...
Sox, the growing concern is the amount of cash that will be needed. Exactly why P results are so important for 2 reasons. One, a partnership would provide instant cash... Two, an up-listing would be more likely with positive news. Leo is the one who mentioned partnership concerning P. For once, lets see if CTIX can deliver a homerun... Singles won't cut it no more....
Why would LEO/Aspire sell shares if good news was approaching? Wouldn't it be logical to raise capital with a rising PPS? As far as low volume goes, it's averaging 200K which is normal. The few days the volume was low, the PPS rose... Hedge your bets now, this stock will be sub-penny or 2 plus in 2 weeks...
Investment? You mean an investment on a rigged market controlled by a few individuals. If that's a sound investment than why can't this trade above 2? Every time this stock approaches 2, it goes right back down. The off-shore folks are playing this investment long/short, praying on the hopefuls to keep buying shares. Leo needed to up-list last-year, so let the OTCBB games continue...
This investment has 2 fates. The P trial fails, stock falls and Leo has no choice but to do a RS to survive. The P trial is a success, stock trades above 2, stock up-lists with a chance for a partnership. The longer picture is either Leo was a great con-man or there will be some rich people around here... All the posts here back and forth are meaningless... 50/50 at this point what occurs... The safe play is to hold off buying shares until P results. Or, trim back some positions.
No, that's the life of a small biotech trading on-the-pinks... Pharma companies don't drop (15 percent) in a week with no negative news... All because Leo failed to up-list during the rally of 2014...
1.50 holds, rally time til the close... Smart money will move back in...
A RS is Leo's only way off penny-land market if P fails. I've been saying that for months. Too many hurdles trying to reach a sustained PPS level to up-list.
Menon needs a new car, sell a few thousand shares here and there. Between Rosen, Menon and the Mako shorts, P better succeed or this could get ugly...
Somebody is dumping at the market... Wonder if it's the same crew from last August after the Mako hit? They don't want CTIX to succeed, so they pile on short positions after any rally. Why being trapped on pink-land has been Leo's worst nightmare.
The weak hands are getting out... Heading for the hills before the
P results... Makes sense in a way, as shares can be purchased later on... The question at what price? 1.20 or 2.20...
I expect positive numbers as well. I have a feeling Leo knows the results... A partnership probably hinges on the data... Wouldn't be surprised if negotiations are on-going. The recent sell-off (low volume) is another great buying opportunity.
If there was a chance results would be delayed why even say May? Just say results are pending when XYZ are met... A May deadline only fuels speculation as the month progresses. We've seen this many times before... What's going on with B/K these days? Seems like this company is stuck in-the-mud...
It's natural for investors to feel nervous considering the importance of a successful P trial. A positive outcome would help financing (partnership), it would relieve the pressure from the Rosen suit and give CTIX a confidence boost. Probably enough to up-list... So much riding on P...
If the results are bad, what would be the rush in posting them? Leo knows the stock will get hammered. How about an update that the results are pending and a progress report on the other drugs? I'm more disappointed in K's lack of progress/news than P results.